Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Manufacturing Roundup – 1 April 2019

Executive Summary

Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.

You may also be interested in...



Zydus Cadila Gets Warning Letter

Zydus Cadila has received a warning letter from the FDA for its Moraiya facility. The company has insisted that it will not affect the existing business in the US where it has filed over 330 ANDAs.

Alkem Grows At Home And Abroad

Alkem said it had a “mixed year”, registering growth in India and internationally despite setbacks that included a weak anti-infectives season and a recent Form 483 from the US Food and Drug Administration.

Manufacturing Round-Up: Sterling Gains A US Site As Normon Invests €100m

Sterling Pharma Solutions has acquired a US facility and Olon has bought a plant from Sandoz, while Normon is investing €100m in manufacturing expansions.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB140201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel